G129R functions as a molecular antagonist to tumor-associated PRL by inducing adaptive autophagic cell death in human ovarian cancer. These preclinical findings reveal the novelty of G129R as an adjuvant therapy for ovarian cancer.
CONCLUSIONS (LOWER RIGHT-HAND CORNER)
1. Prolactin antagonist, G129R, inhibits ovarian cancer growth and progression; 2. PRLR is required for G129R induced autophagy; 3. PEA-15 mediates autophagic cell death induced by blocking PLR/PRLR signaling;
– LINKED PHOTOS & VIDEOS SHOW "FACTUAL" INFORMATION & PROVIDE EVIDENCE TO "CLAIMS". – "A PICTURE IS WORTH 1000 WORDS"!!!—an old saying – PHOTOS/VIDEOS DON'T LIE.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.